Join us for an expert panel webinar on the just-released PRECISE Trial 1-year results that showed using coronary CTA with FFRCT Analysis to evaluate suspected coronary artery disease offers more accurate non-invasive diagnosis, fewer unnecessary tests and higher confidence among physicians in identifying patients needing treatment. The data demonstrates AHA/ACC Chest Pain Guideline-directed CCTA plus FFRCT Precision Pathway is superior to traditional testing. Watch now!